Skip to main content
. 2022 Aug 20;12:14219. doi: 10.1038/s41598-022-18391-6

Table 2.

Comparison of the changes from baseline in overactive bladder symptoms, heart rate variability cardio-ankle vascular index and ankle-brachial pressure index after 12-week treatment between the mirabegron and solifenacin groups.

Variable Mirabegron (n = 43) Solifenacin (n = 44) P
OABSS
Daytime frequency 0 (− 1, 0)** 0 (− 1, 0)** 0.23
Nocturia 0 (− 1, 0)** 0 (− 1, 0)* 0.17
Urgency − 1 (− 3, 0)** − 1 (− 3, 0)** 0.71
Urgency incontinence 0 (− 1, 0)* − 1 (− 2, 0)** 0.11
OABSS total score − 3 (− 5, − 1)** − 3 (− 5, − 1)** 0.75
SDNN (ms) − 1.9 (− 11.4, 5.4) 1.2 (− 5.4, 6.1) 0.14
RMSSD (ms) − 2.1 (− 12.5, 6.5) 0.0 (− 5.5, 9.0) 0.29
NN50 0 (− 5.5, 2.5) 0 (− 5.1, 4.4) 0.81
pNN50 (%) 0 (− 2.2, 0.8) 0 (− 0.7, 2.5) 0.26
SD1 − 1.5 (− 8.8, 4.6) 0.0 (− 3.9, 6.5) 0.27
SD2 − 5.3 (− 17.8, 5.7) 0.8 (− 7.7, 8.6) 0.14
SD1/SD2 − 0.01 (− 0.14, 0.14) 0.01 (− 0.06, 0.14) 0.44
VLF(ms2) − 53 (− 138.5, 81) 15.8 (− 72.3, 67.8) 0.12
LF (ms2) − 2 (− 96.5, 41) − 0.8 (− 22.4, 89.8) 0.33
HF (ms2) − 3 (− 125, 52.5) 2.8 (− 51.9, 200.8) 0.23
Total Power (ms2) − 35.5 (− 432, 185.5) 6.3 (− 146.1, 509.5) 0.20
LF norm (n.u.) 0.4 (− 12.3, 8.7) − 3.0 (− 10.5, 9.0) 0.71
HF norm (n.u.) − 0.4 (− 8.7, 12.3) 3.0 (− 9.0, 10.6) 0.70
LF/HF 0.02 (− 0.48, 0.25) − 0.13 (− 0.45, 0.25) 0.89
SBP of right brachial artery (mmHg) 0 (− 12, 7) − 5.5 (− 14.8, 1.3)** 0.09
DBP of right brachial artery (mmHg) − 0.5 (− 5.3, 6) − 3 (− 7, 3)* 0.24
SBP of left brachial artery (mmHg) 0 (− 6.3, 8.3) − 4.5 (− 13.8, 5)* 0.13
DBP of left brachial artery (mmHg) − 2 (− 7.3, 3) − 3.5 (− 10.8, 2)** 0.25
SBP of right ankle artery (mmHg) 0 (− 10.5, 7.3) − 4.5 (− 10.8, 4.8)* 0.33
DBP of right ankle artery (mmHg) 0.5 (− 4, 3) − 0.5 (− 8.8, 4.8) 0.71
SBP of left ankle artery (mmHg) − 2 (− 9, 4.8) − 5.5 (− 16.8, 4.8)* 0.21
DBP of left ankle artery (mmHg) − 1 (− 5, 2) − 1 (− 7.8, 4.5) 0.17
Heart rate (per min) 2 (− 2.3, 7)* 1 (− 4, 7) 0.49
CAVI − 0.05 (− 0.44, 0.40) − 0.05 (− 0.69, 0.66) 0.88
ABI 0.01 (− 0.05, 0.05) 0.00 (− 0.04, 0.05) 0.99

Data are expressed as median (interquartile range). Changes from baseline are the subtraction of pretreatment values from posttreatment values. Abbreviations are as in Table 1.

Within-group comparisons of baseline and posttreatment values were performed by Wilcoxon signed-rank test. *p < 0.05, and **p < 0.01.

Wilcoxon rank-sum test.